![HIZENTRA (immune globulin [human]) 20% liquid by CSL Behring](https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/hizentra_91291.jpg)
CSL Behring announced that the FDA has expanded the administration options for Hizentra (immune serum globulin [human]) 0.2mg/mL (20%) liquid for SC injection to include dosing once every 2 weeks in addition to weekly dosing for patients with primary immunodeficiency.
RELATED: Immune Disorders Resource Center
The FDA approved the bi-weekly dosing for Hizentra based on the principles of pharmacometrics and pharmacokinetic modeling.
The new dosing option allows greater flexibility by allowing patients to self-administer less frequently. Hizentra delivers consistent levels of immunoglobulin G (IgG) replacement therapy to help protect those with PI against infections.
Continue Reading
Hizentra received FDA approval in March 2010 as a once-weekly immunoglobulin G (IgG) replacement therapy.
For more information call (800) 504-5434 or visit Hizentra.com.
